Non-steroidal progesterone receptor modulators

Expert Opinion on Therapeutic Patents

Volumn 13, Issue 12, 2003, Pages 1839-1847

  Zhang, Puwen ^a   Fensome, Andrew ^a   Wrobel, Jay ^a   Winneker, Richard ^a   Zhang, Zhiming ^a  

^a PFIZER INC   (United States)

Author keywords

Contraception; Endometriosis; Hormone therapy; PR agonists; PR antagonists; Progesterone receptor (PR); Uterine fibroids

Indexed keywords

5 ARYL 1,3 DIHYDROBENZO[C]ISOTHIAZOLE 2,2 DIOXIDE DERIVATIVE; 5 ARYL 1,3, DIHYDROINDOL 2 ONE DERIVATIVE; 5 ARYL 3,4 DIHYDROINDOLE 2 THIONE DERIVATIVE; 6 ARYL 1,3 DIHYDROBENZOIMIDAZOL 2 ONE DERIVATIVE; 6 ARYL 1,4 DIHYDRO 2H BENZO[D][1,3]OXAZINE DERIVATIVE; 6 ARYL 1,4 DIHYDROBENZO[D][1,3]OXAZIN 2 ONE DERIVATIVE; 6 ARYL 1,4 DIHYDROBENZO[D][1,3]OXAZINE 2 THIONE DERIVATIVE; 6 ARYLQUINAZOLIN 2 ONE DERIVATIVE; 6 ARYLQUINOLIN 2 ONE DERIVATIVE; AMIDE; AMIDINE; BENZIMIDAZOLE DERIVATIVE; BENZOXAZINE DERIVATIVE; CONTRACEPTIVE AGENT; INDOLE DERIVATIVE; ISOTHIAZOLE DERIVATIVE; MEDROXYPROGESTERONE ACETATE; MIFEPRISTONE; OXAZOLIDINE DERIVATIVE; PROGESTERONE RECEPTOR MODULATOR; PYRROLE DERIVATIVE; QUINAZOLINE DERIVATIVE; QUINOLINE DERIVATIVE; STEROID RECEPTOR; THIAZOLIDINE DERIVATIVE; UNCLASSIFIED DRUG; UREA DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; BREAST CARCINOMA; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; ENDOMETRIOSIS; FEMALE; HEADACHE; HORMONAL THERAPY; HUMAN; LUNG CARCINOMA; MASTALGIA; NAUSEA; NONHUMAN; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; REPRODUCTION; REVIEW; STRUCTURE ACTIVITY RELATION; UTERUS MYOMA;

EID: 0346121424     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.13.12.1839     Document Type: Review

References (42)

1. PSYCHOYOS A: Hormonal control of ovoimplantation. Vitam. Horm. (1973) 31:201-256.
2. LYNDON JP, DEMAY O, FUNK CR et al.: Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev. (1995) 9:266-2278.
3. ZHANG Z, FUNK C, GLASSER SR, MULHOLLAND J: Progesterone regulation of heparin-binding epidermal growth factor-like growth factor gene expression during sensitization and decidualization in the rat uterus: effects of the antiprogestin, ZK-98299. Endocrinology (1994) 135(3):1256-1263.
4. MANI SY, ALLEN JMC, CLARK JH, BLAUSTEIN JD, O'MALLEY BW: Convergent pathways for steroid hormone- and neurotransmitter-induced rat sexual behavior. Science (1994) 265(5176):1246-1249.
5. EVENS RW: The steroid and thyroid hormone receptor superfamily. Science (1988) 240:889-895.
6. TSAI MJ, O'MALLEY BW: Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Ann. Rev. Biochem. (1994) 63:451-486.
7. KASTNER P, KRUST A. TURCOTTE B et al.: Two distinct oestrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J. (1990) 9(5):1603-1614.
8. CONNEELY OM, MAXWELL BL, TOFT DO, SCHRADER WT, O'MALLEY BW: The A and B forms of the chicken progesterone receptor arise by alternate initiation of translation of a unique mRNA. Biochem. Biophys. Res. Commun. (1987) 149(2):493-501.
9. CONNEELY OM, MULAC-JERICEVIC B, LYDON JP, DE MAYO FJ: Reproductive functions of the progesterone receptor isoforms: lessons fiorn knockout mice. Mol. Cell. Endocrin. (2001) 179(1-2):97-103.
10. MULAC-JERICEVIC B, MULLINAX RA, DEMAYO FJ, LYDON JP, CONNEELY OM: Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform. Science (2000) 289(5485):1751-1754.
11. MANGAL RK, WIEHLE RD, POINDEXTER AN, WEIGEL NL: Differential expression of uterine progesterone receptor forms A and B during the menstrual cycle. J. Steroid Biochem. Mol. Biol. (1997) 63(4-6):195-202.
12. FUJIMOTO J, ICHIGO S, HIROSE R, SAKAGUCHI H, TAMAYA T: Clinical implication of expression of progesterone receptor form A and B mRNAs in secondary spreading of gynecologic cancers. J. Steroid Biochem. Mol. Biol. (1997) 62(5/6):449-454.
13. EDGREN RA, STURTEVANT FM: Potencies of oral contraceptives. Am. J. Obst. Gynecol. (1976) 125(8):1029-1038.
14. BROGDEN RN, GOA KL, FAULDS D: Mifepristone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs (1993) 45(3):384-409.
15. GLASIER A, BAIRD D: The effects of self-administering emergency contraception. New Engl. J. Med. (1998) 339:1.
16. SLAYDEN OD, ZELINSKI-WOOTEN MB, CHWALISZ K, STOUFFER RL, BRENNER RM: Chronic treatment of cycling rhesus monkeys with low doses of the antiprogestin ZK-137316: morphometric assessment of the uterus and oviduct. Human Reprod. (1998) 13(2):269-277.
17. ZELINSKI-WOOTEN MB, SLAYDEN OD, CHWALISZ K, HESS DL, BRENNER RM, STOUFFER RL: Chronic treatment of female rhesus monkeys with low doses of the antiprogestin ZK-137316: establishment of a regimen that permits normal menstrual cyclicity. Human Reprod. (1998) 13(2):259-267.
18. KETTEL LM, MURPHY, AA, MORALES AJ, YEN SS: Clinical efficacy of die antiprogesterone RU-486 in the treatment of endometriosis and uterine fibroids. Human Reprod. (1994) 9(Suppl. 1):116-120.
19. KETTEL LM, MURPHY AA, MORALESAJ, YEN SS: Preliminary report on the treatment of endometriosis with lowdose mifepristone (RU-486). Am. J. Obst. Gynecol. (1998) 178:1151-1156.
20. MURPHY AA, KETTEL LM, MORALES AJ, ROBERTS VJ, YEN SS: Regression of uterine leiomyomata in response to the antiprogesterone RU-486. J. Clin. Endocrinol. Metabol. (1993) 76:513-517.
21. BRENNER RM, SLAYDEN OD, CRITCHLEY HOD: Antiproliferative effects of progesterone antagonists in the primate endometrium: a potential role for the androgen receptor. Reproduction (2002) 124(2):167-172.
22. KARAS RH, VAN EICKELS M, LYDON JP et al.: A complex role for the progesterone receptor in the response to vascular injury. J. Clin. Investigation (2001) 108:611-618.
23. ROSANO GMC, FINI M: Comparative cardiovascular effects of different PR agonists in menopause. Int. J. Fertility and Women's Medecine (2001) 46:248-256.
24. SKOUBY SO, PETERSEN KR: Clinical experience with the recently developed progestogens. Int. J. Fertility (1991) 36(Suppl.1):32-37.
25. WELLINGTON K, PERRY CM: Estradiol valerate/dienogest. Drugs (2002) 62.491-504.
26. ZHI L, TEGLEY CM, PIO B et al.: Non-steroidal progesterone receptor antagonists based on 6-thiophenylhydroquinolines. Bioorg. Med. Chem. Lett. (2000) 10:415-418.
27. ZHANG P, TEREFENKO EA, FENSOME A et al.: Potent non-steroidal progesterone receptor agonists: synthesis and SAR study of 6-aryl benzoxazines. Bioorg. Med. Chem. Lett. (2002) 12:787-790.
28. BECK CA, WEIGEL NL, MOYER ML, NORDEEN SK, EDWARDS DP: The progesterone antagonist RU-486 acquires agonist activity upon stimulation of cAMP signalling pathways. Proc. Natl. Acad. Sci. USA (1993) 90:4441-4445.
29. ZHANG Z, LUNDEEN SG, ZHU Y, CARVER JM, WINNEKER RC: In vitro characterization of trimegestone: a new potent and selective progestin. Steroids (2000) 65:637-643.
30. ZRANG P, TEREFENKO EA, FENSOME A, WROBEL J, WINNEKER R, ZHANG Z: Novel 6-aryl-1,4-dihydrobenzo[d]oxazine-2-thiones as potent, selective and orally-active non-steroidal progesterone receptor agonists. Bioorg. Med. Chem. Lett. (2003) 13(7):1313-1316.
31. FENSOME A, KOKO M, WROBEL J et al.: Novel 5-aryl-1,3-dihydro-indole-2-thiones: potent, orally-active progesterone receptor agonists. Bioorg. Med. Chem. Lett. (2003) 13(7):1317-1320.
32. LUNDEEN SG, MANG Z, ZHU Y, CARVER JM, WINNEKER RC: Rat uterine complement C3 expression as a model for progesterone receptor modulators: characterization of the new progestin trimegestone. J. Steroid Biochem. Mol. Biol. (2001) 78(2):137-143.
33. HORWITZ KB, TUNG L, TAKIMOTO GS: Progestins, progesterone receptors and breast cancer. Horm. Cancer (1996) 283-306.
34. KLIJN JGM, SETYONO-HAN B, FOEKENS JA: Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer. Steroids (2000) 65:825-830.
35. MICHNA H, PARCZYK K, SCHNEIDER MR, NISHINO Y: Differentiation therapy with progesterone antagonists. Ann. NY Acad. Sci. (1995) 761:224-247.
36. ROSEN J, DAY A, JONES TK, JONES ETT, NADZAN AM, STEIN RB: Intracellular receptors and signal transducers and activators of transcription superfamilies: novel targets for small-molecule drug discovery. J. Med. Chem. (1995) 38(25):4855-4874.
37. ZHANG P, TEREFENKO EA, WROBEL J et al.: Synthesis and progesterone receptor antagonist activities of 6-aryl benzimidazolones and benzothiazolones. Bioorg. Med. Chem. Lett. (2001) 11(20):2747-2750.
38. FENSOME A, BENDER R, COHEN J et al.: New progesterone receptor antagonists: 3,3-disubstituted-5-aryloxindoles. Bioorg. Med. Chem. Lett. (2002) 12(23):3487-3490.
39. ZHANG P, TEREFENKO EA, FENSOME A et al.: 6-Aryl-1,4-dihydro-benzo[d][1,3]oxazin-2-ones: a novel class of potent, selective and orally-active nonsteroidal progesterone receptor antagonists. J. Med. Chem. (2002) 45(20):4379-4382.
40. PHILIBERT D, BOUCHOUX F, DEGRYSE M, LECAQUE D, PETIT F, GAILLARD M: The pharmacological profile of a novel norpregnance progestin (trimegestone). Gynecol. Endocrinol. (1999) 13:316-326.
41. ZHI L, TEGLEY CM, PIO B et al.: 5-Benzylidene-1,2-dihydrochromeno[3,4-f]quinolines as selective progesterone receptor modulators. J. Med. Chem. (2003) 46(19):4104-4112.
42. MULAC-JERICEVIC B, LYDON JP, DEMAYO FJ, CONNEELY OM: Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform. Proc. Natl. Acad. Sci USA (2003) 100(17):9744-9749.